TARA

Protara Therapeutics, Inc. (TARA) | Rumor.io

Protara Therapeutics

TARA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,965

Bullish sentiment (50-day avg)100%

Price to earnings ratio-2.43

Market capitalization192.1M

Earnings per share-1.36

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-57.4M

Social

What share of all stock conversation is about TARA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Feb 24

$TARA's "BCG-like" product in development has a more reliable manufacturing process than BCG, which has a 40-50% failure rate in late-stage batches.
Analysts forecast $TARA as the first approved non-BCG option for BCG-naïve patients, addressing shortages and access issues in the market.
$TARA has a 68% complete response rate at six months in the BCG-unresponsive cohort of the ADVANCED-2 trial, with a favorable safety profile and promising durability for the treatment.

Generated by AI

Sentiment

Of the messages about TARA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	92.59% +2.1
Bearish	—	0% 0	0% 0	7.41% -2.1

Bullish· Feb 24

Protara Therapeutics' TARA-002 has shown a 68% complete response rate at 6 months in BCG-unresponsive patients with carcinoma in situ (CIS), with a favorable safety profile.
The company's upcoming conferences will provide more information for large investors, making it an attractive hold for shares.
The recent 75M capital raise has left TARA with full cash coffers, positioning the company for future growth and development of its bladder cancer therapy and other treatments.

Bearish· Dec 6

The company's stock has been heavily shorted, with some users predicting that anyone shorting the stock is "absolutely fooked".
The stock's recent price action has been seen as a "dead cat bounce play", with some users predicting that it will eventually reverse split and decline in value.
The company's sector is highly competitive and dominated by top players, making it difficult for the company to grow, with some users predicting that the stock is "not going nowhere" besides a reverse split.

Generated by AI

Topics

Of the messages about TARA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	80.73%
Announcements	—	—	—	12.33%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	1.42%
Technical Analysis	—	—	—	5.52%

Announcements· Dec 5

Protara Therapeutics, Inc. ($TARA) announced positive results from the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC), showing a 72% six-month complete response rate and 100% CR in BCG-unresponsive patients.
The trial's results led to a 116% surge in $TARA stock, with a 80% complete response rate at any time point and a 100% CRR at six months within the BCG-unresponsive cohort with carcinoma in situ (CIS) only.
The company's TARA-002 demonstrated favorable safety and tolerability, with no Grade 2 or greater treatment-related adverse events, and a 80% reinduction salvage rate with compelling durability observed from three to six months across BCG exposures.

Technical Analysis· Dec 5

$TARA has formed an inverse head and shoulders pattern on the monthly chart, with a potential target of $5 for the December or January monthly candle.
The stock has been halted to the downside at $8.74, having failed to reach its momentum trigger at $11.25, and will be closely monitored for any necessary adjustments.
$TARA has broken out above major resistance, indicating a higher probability of upside continuation, and has been identified as a potential trade opportunity with a target of $5.70.

Generated by AI

Community

Of the messages about TARA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	23.07%
Newcomers	—	0%	0%	76.93%

Regulars· Dec 5

The regulars are optimistic about the asset's prospects, citing the company's Phase 2 trial results showing a 72% six-month complete response rate and no severe treatment-related adverse events.
The asset's market capitalization is undervalued, with some regulars estimating it to be 10 times cheaper than a comparable company, despite the latter's drug being in Phase 3.
The regulars are excited about the asset's data, with one stating that the company's results are "very competitive" and another noting that the stock has surged 116% on the trial's positive results.

Newcomers· Feb 24

Newcomers are excited about Protara Therapeutics' Phase II trial update, highlighting a 68% complete response rate at six months in BCG-unresponsive non-muscle invasive bladder cancer patients.
Some traders are looking to buy into Protara Therapeutics after a 15% after-hours slump, considering it a potential bargain after new bladder cancer data was released.
The company's experimental bladder cancer drug, TARA-002, has shown encouraging results in a Phase II trial, with a robust 6/12-month complete response rate in BCG-unresponsive and naïve NMIBC cohorts.

Generated by AI

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 2:00 pm ET. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.c

21d agoYahoo Finance

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

1mo agoYahoo Finance

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

1mo agoSeeking Alpha

What Makes Protara Therapeutics (TARA) a New Buy Stock

Protara Therapeutics (TARA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2mo agoYahoo Finance

Also Discussed

Investors talking about TARA also mention

#	Name	Attention
1	Cardiff Oncology Inc.CRDF	0%+0
2	OBLN - Obalon Therapeutics, Inc.	——
3	Legacy Education Inc.LGCY	0%new
4	Eltek Ltd.ELTK	0%new
5	Immunic, Inc.IMUX	0%0
6	Alpha Metallurgical Resources, Inc.AMR	0%0
7	Outlook Therapeutics Inc.OTLK	0.01%-0.01
8	SLRX - Salarius Pharmaceuticals, Inc.	——
9	Precipio Inc.PRPO	0%0
10	Viveve Medical Inc.VIVE	0%0

Protara Therapeutics, Inc.

Healthcare
Biotechnology

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its current pipeline centers on TARA-002, an investigational cell therapy being studied for non-muscle invasive bladder cancer and lymphatic malformations, and intravenous choline chloride, a phospholipid substrate replacement therapy for patients receiving parenteral nutrition. The company’s programs address areas with significant unmet medical need across oncology, rare disease, gastrointestinal, and metabolic care. Protara Therapeutics operates as a research-driven developer of specialty treatments, with its portfolio aimed at advancing targeted options for patient populations that have limited approved alternatives. Headquartered in New York, New York, the company focuses on clinical development and translational science to support its therapeutic candidates.

Website

Location

345 Park Avenue South

New York, NY, 10010

United States

Social

What share of all stock conversation is about TARA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Feb 24

$TARA's "BCG-like" product in development has a more reliable manufacturing process than BCG, which has a 40-50% failure rate in late-stage batches.
Analysts forecast $TARA as the first approved non-BCG option for BCG-naïve patients, addressing shortages and access issues in the market.
$TARA has a 68% complete response rate at six months in the BCG-unresponsive cohort of the ADVANCED-2 trial, with a favorable safety profile and promising durability for the treatment.

Generated by AI

Sentiment

Of the messages about TARA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	92.59% +2.1
Bearish	—	0% 0	0% 0	7.41% -2.1

Bullish· Feb 24

Protara Therapeutics' TARA-002 has shown a 68% complete response rate at 6 months in BCG-unresponsive patients with carcinoma in situ (CIS), with a favorable safety profile.
The company's upcoming conferences will provide more information for large investors, making it an attractive hold for shares.
The recent 75M capital raise has left TARA with full cash coffers, positioning the company for future growth and development of its bladder cancer therapy and other treatments.

Bearish· Dec 6

The company's stock has been heavily shorted, with some users predicting that anyone shorting the stock is "absolutely fooked".
The stock's recent price action has been seen as a "dead cat bounce play", with some users predicting that it will eventually reverse split and decline in value.
The company's sector is highly competitive and dominated by top players, making it difficult for the company to grow, with some users predicting that the stock is "not going nowhere" besides a reverse split.

Generated by AI

Topics

Of the messages about TARA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	80.73%
Announcements	—	—	—	12.33%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	1.42%
Technical Analysis	—	—	—	5.52%

Announcements· Dec 5

Protara Therapeutics, Inc. ($TARA) announced positive results from the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC), showing a 72% six-month complete response rate and 100% CR in BCG-unresponsive patients.
The trial's results led to a 116% surge in $TARA stock, with a 80% complete response rate at any time point and a 100% CRR at six months within the BCG-unresponsive cohort with carcinoma in situ (CIS) only.
The company's TARA-002 demonstrated favorable safety and tolerability, with no Grade 2 or greater treatment-related adverse events, and a 80% reinduction salvage rate with compelling durability observed from three to six months across BCG exposures.

Technical Analysis· Dec 5

$TARA has formed an inverse head and shoulders pattern on the monthly chart, with a potential target of $5 for the December or January monthly candle.
The stock has been halted to the downside at $8.74, having failed to reach its momentum trigger at $11.25, and will be closely monitored for any necessary adjustments.
$TARA has broken out above major resistance, indicating a higher probability of upside continuation, and has been identified as a potential trade opportunity with a target of $5.70.

Generated by AI

Community

Of the messages about TARA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	23.07%
Newcomers	—	0%	0%	76.93%

Regulars· Dec 5

The regulars are optimistic about the asset's prospects, citing the company's Phase 2 trial results showing a 72% six-month complete response rate and no severe treatment-related adverse events.
The asset's market capitalization is undervalued, with some regulars estimating it to be 10 times cheaper than a comparable company, despite the latter's drug being in Phase 3.
The regulars are excited about the asset's data, with one stating that the company's results are "very competitive" and another noting that the stock has surged 116% on the trial's positive results.

Newcomers· Feb 24

Newcomers are excited about Protara Therapeutics' Phase II trial update, highlighting a 68% complete response rate at six months in BCG-unresponsive non-muscle invasive bladder cancer patients.
Some traders are looking to buy into Protara Therapeutics after a 15% after-hours slump, considering it a potential bargain after new bladder cancer data was released.
The company's experimental bladder cancer drug, TARA-002, has shown encouraging results in a Phase II trial, with a robust 6/12-month complete response rate in BCG-unresponsive and naïve NMIBC cohorts.

Generated by AI

Protara Therapeutics

Social

Feb 24

Sentiment

Bullish· Feb 24

Bearish· Dec 6

Topics

Announcements· Dec 5

Technical Analysis· Dec 5

Community

Regulars· Dec 5

Newcomers· Feb 24

News

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

What Makes Protara Therapeutics (TARA) a New Buy Stock

Also Discussed

Protara Therapeutics, Inc.

Company Information

Location

News

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

What Makes Protara Therapeutics (TARA) a New Buy Stock

Also Discussed

Social

Feb 24

Sentiment

Bullish· Feb 24

Bearish· Dec 6

Topics

Announcements· Dec 5

Technical Analysis· Dec 5

Community

Regulars· Dec 5

Newcomers· Feb 24